Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLH | Q9Y253 | 8/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | APEX1 | P27695 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | MMP1 | P03956 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.84 |
| ▸ | PLG | P00747 | 1/20 | 0.84 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.82 |
| ▸ | TUBB | P07437 | 1/20 | 0.82 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.82 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.82 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3-O-Methylquercetin SCHEMBL29897544 | 1.00 | POLH (1.00) | POLHKDM4EPOLBAPEX1RECQL | |
| SCHEMBL828941 | 0.91 | PLG (1.00) | POLHKDM4EPOLBAPEX1RECQL | |
| SCHEMBL29825010 | 0.91 | PLG (1.00) | POLHKDM4EPOLBAPEX1RECQL | |
| SCHEMBL30266565 | 0.90 | TUBB4A (1.00) | POLHKDM4EPOLBAPEX1RECQL | |
| SCHEMBL17102291 | 0.90 | POLH (0.82) | POLHKDM4EPOLBAPEX1RECQL | |
| SCHEMBL15676566 | 0.90 | TUBB4A (1.00) | POLHKDM4EPOLBAPEX1RECQL | |
| SCHEMBL1250534 | 0.90 | TUBB4A (1.00) | POLHKDM4EPOLBAPEX1RECQL | |
| SCHEMBL13780248 | 0.90 | POLH (0.82) | POLHKDM4EPOLBAPEX1RECQL | |
| SCHEMBL31230209 | 0.90 | TUBB4A (1.00) | POLHKDM4EPOLBAPEX1RECQL | |
| SCHEMBL10026580 | 0.90 | POLH (0.82) | POLHKDM4EPOLBAPEX1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 511 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12514278-B2 | Tobacco-derived composition | R.J. REYNOLDS TOBACCO COMPANY (US) | 2026-01-06 | — | — | US | claimed |
| US-20250319058-A1 | COMPOSITIONS AND METHODS USING A COMBINATION OF FISETIN AND QUERCETIN FOR CELLULAR ENERGY | NESTLE SA (CH) | 2025-10-16 | — | — | US | claimed |
| US-20250312307-A1 | COMPOSITIONS AND METHODS USING A COMBINATION OF FISETIN AND QUERCETIN FOR USE IN CARTILAGE DEGENERATION | NESTLE SA (CH) | 2025-10-09 | — | — | US | claimed |
| CN-118511948-B | Vacuum freeze-dried feed for climbing pets and preparation method thereof | 青岛大任富城畜牧有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-119095594-A | Compositions and methods for cartilage degradation using a combination of fisetin and quercetin | 雀巢产品有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-119072309-A | Compositions and methods for using a combination of neisseria and quercetin for cellular energy | 雀巢产品有限公司 | 2024-12-03 | — | — | CN | claimed |
| CN-118680921-A | Hypoglycemic compound and application thereof | 广东省科学院广州地理研究所 | 2024-09-24 | — | — | CN | claimed |
| CN-118615276-A | Compound for inhibiting alpha-glucosidase and application thereof | 广东省科学院广州地理研究所 | 2024-09-10 | — | — | CN | claimed |
| CN-118511948-A | Vacuum freeze-dried feed for climbing pets and preparation method thereof | 青岛大任富城畜牧有限公司 | 2024-08-20 | — | — | CN | claimed |
| CN-118304334-A | Preparation and application of traditional Chinese medicine fructus rhodomyrti liver protection active ingredient | 北京工业大学 | 2024-07-09 | — | — | CN | claimed |
| US-20050042311-A1 | Use of an opuntia ficus-indica extract and compounds isolated therefrom for protecting nerve cells | AGRICULTURAL CORPORATIVE SE.JONG CO. (KR) | 2005-02-24 | — | — | US | claimed |
| EP-1448188-A1 | USE OF AN OPUNTIA FICUS-INDICA EXTRACT AND COMPOUNDS ISOLATED THEREFROM FOR PROTECTING NERVE CELLS | Korea Institute of Science and Technology (KR) | 2004-08-25 | — | — | EP | claimed |
| US-20040162247-A1 | Therapeutic agent or osteoporosis comprising an active ingredient of quercetin derivatives | KIM CHUNG-SOOK (KR) | 2004-08-19 | — | — | US | claimed |
| WO-2004052351-A1 | NOVEL USE OF LYCOPENE | DSM IP ASSETS B.V. (CH) | 2004-06-24 | — | — | WO | claimed |
| CN-1442146-A | New pharmaceutical of cactus total flavone and its preparation method | SHENYANG UNIV OF MEDICINE (CN) | 2003-09-17 | — | — | CN | claimed |
| EP-1309326-A1 | A THERAPEUTIC AGENT OF OSTEOPOROSIS COMPRISING AN ACTIVE INGREDIENT OF QUERCETIN DERIVATIVES | Korea Institute of Oriental Medicine (KR) | 2003-05-14 | — | — | EP | claimed |
| WO-2003037324-A1 | USE OF AN OPUNTIA FICUS-INDICA EXTRACT AND COMPOUNDS ISOLATED THEREFROM FOR PROTECTING NERVE CELLS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2003-05-08 | — | — | WO | claimed |
| US-20020165169-A1 | Therapeutic agent of osteoporosis comprising an active ingredient of quercetin derivatives | KOREA INSTITUTE OF ORIENTAL MEDICINE (KR) | 2002-11-07 | — | — | US | claimed |
| WO-2002017909-A1 | A THERAPEUTIC AGENT OF OSTEOPOROSIS COMPRISING AN ACTIVE INGREDIENT OF QUERCETIN DERIVATIVES | KOREA INSTITUTE OF ORIENTAL MEDICINE (KR) | 2002-03-07 | — | — | WO | claimed |
| WO-2001003687-A2 | METHOD AND COMPOSITIONS FOR INHIBITING BIOSYNTHESIS OR BIOACTIVITY OF ENDOGENOUS STEROID SEX HORMONES IN HUMANS | CEDARS-SINAI MEDICAL CENTER (US) | 2001-01-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162247-A1 | Therapeutic agent or osteoporosis comprising an active ingredient of quercetin derivatives | NFATC1, MKI67, SOST | POLH 3604/4885KDM4E 952/4885POLB 3516/4885 |
| US-20020165169-A1 | Therapeutic agent of osteoporosis comprising an active ingredient of quercetin derivatives | NFATC1, MKI67, SOST | POLH 3627/4885KDM4E 893/4885POLB 3525/4885 |
| US-20050042311-A1 | Use of an opuntia ficus-indica extract and compounds isolated therefrom for protecting nerve cells | ACHE, CHAT, NOTUM | POLH 3904/4885KDM4E 4050/4885POLB 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.